Tissue-Engineered Human Models of Cardiac Disease: A Case Study of Friedreich’s Ataxia (FRDA), Upcoming Webinar Hosted by Xtalks

Share Article

Friedreich’s ataxia (FRDA) is an autosomal recessive disease that affects mainly the peripheral and central nervous systems, and heart. Currently, there are few effective treatments to manage progressive disability. Human pluripotent stem cells (hPSCs) and tissue-engineered models of FRDA hold promise for the discovery of novel therapeutics. Join this free webinar to learn about using an in vitro human-based FRDA model that is suitable for understanding FRDA pathogenesis and pharmaceutical testing.

Xtalks Life Science Webinars

The data suggest that tissue-engineered models fabricated using hPSC-derived ventricular cardiac cells cultured as anisotropic sheets and 3D tissue strips are key in understanding the pathogenesis of FRDA cardiomyopathy, and are suitable for pharmaceutical testing.

Tissue-engineered human in vitro models represent an important paradigm shift in the study of Friedreich’s ataxia (FRDA) and other genetic cardiomyopathies including Barth syndrome, left ventricular noncompaction, hypoplastic left heart syndrome, familial hypertrophic cardiomyopathy and others. These human-relevant models hold the promise of revolutionizing the manner in which drugs are currently discovered and developed.

Join Bernard Fermini, Chief Research & Development Officer at Novoheart in a live webinar on Wednesday, October 30, 2019 at 12pm EDT to learn about the use of human pluripotent stem cells (hPSCs) and tissue-engineered models to study FRDA cardiomyopathy. Human ventricular cardiac anisotropic sheets (hvCAS) and tissue strips (hvCTS) were generated from human embryonic stem cell (hESC) and induced pluripotent stem cell (hiPSC)-derived ventricular cardiomyocytes (VCMs) for modelling FRDA’s electrophysiological and contractile defects, respectively.

The findings show that human-based FRDA in vitro models provide a biomimetic platform suitable to facilitate the study of the disease. The data suggest that tissue-engineered models fabricated using hPSC-derived ventricular cardiac cells cultured as anisotropic sheets and 3D tissue strips are key in understanding the pathogenesis of FRDA cardiomyopathy, and are suitable for pharmaceutical testing.

For more information or to register for this free webinar, visit Tissue-Engineered Human Models of Cardiac Disease: A Case Study of Friedreich’s Ataxia (FRDA).

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:
Candice Tang
Tel: +1 (416) 977-6555 ext 400
Email: ctang@xtalks.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Candice Tang
Xtalks
+1 (416) 977-6555 x400
Email >
Visit website